StrongDecrease
Fasting Plasma Glucose (FPG)
HRS-7535 (15 mg) → Fasting Plasma Glucose (FPG)
HRS-7535 (15 mg) → Fasting Plasma Glucose (FPG)
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
HRS-7535 improves glycemic control in adults with type 2 diabetes
Key finding
HbA1c level decreased by 1.19% (95% CI, -1.54% to -0.84%) with the 15 mg dose.
This study evaluated the efficacy and safety of HRS-7535 in adults with type 2 diabetes inadequately controlled with metformin, showing significant reductions in HbA1c and fasting plasma glucose levels.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Some Concerns bias
Last updated July 4, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
HRS-7535 (15 mg), HRS-7535 (30 mg), HRS-7535 (60 mg), HRS-7535 (90 mg), Placebo
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Primary outcome
HbA1c
Comparator
Placebo
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the efficacy and safety of HRS-7535 in adults with type 2 diabetes inadequately controlled with metformin, showing significant reductions in HbA1c and fasting plasma glucose levels.
Clinical relevance
These findings are significant as they suggest that HRS-7535 could be an effective treatment option for adults with type 2 diabetes who are not achieving adequate glycemic control with metformin alone. Improved blood sugar management can lead to better overall health outcomes and reduce the risk of diabetes-related complications.
Keep in mind
The study's population may not represent all adults with type 2 diabetes. Long-term safety and efficacy data are lacking. The sample size for each treatment group may limit generalizability.
Published in
Journal Reference
Publication details and source links for this paper.
Lixin G, Zilin S, Lihui Z, et al. Efficacy and Safety of HRS-7535 in Adults with Type 2 Diabetes Inadequately Controlled with Metformin. JAMA Network Open. 2026;9(6):e2615622. doi:10.1001/jamanetworkopen.2026.15622
Save this study and add notes to your research library.
Main Effects
HRS-7535 (15 mg) reduced HbA1c by 1.19% (p=0.001).
HRS-7535 (30 mg) reduced HbA1c by 1.59% (p=0.001).
HRS-7535 (60 mg) reduced HbA1c by 1.82% (p=0.001).
HRS-7535 (90 mg) reduced HbA1c by 1.64% (p=0.001).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to HRS-7535 (15 mg), HRS-7535 (30 mg), HRS-7535 (60 mg), and 1 more and Fasting Plasma Glucose (FPG), HbA1c.
This study contributes evidence to
Primary intervention
HRS-7535 (15 mg)
Primary outcomes
- Fasting Plasma Glucose (FPG)
- HbA1c
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
2
Related topics
8
Evidence pairs
270
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongDecrease
HbA1c
HRS-7535 (15 mg) → HbA1c
HRS-7535 (15 mg) → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
StrongDecrease
Fasting Plasma Glucose (FPG)
HRS-7535 (30 mg) → Fasting Plasma Glucose (FPG)
HRS-7535 (30 mg) → Fasting Plasma Glucose (FPG)
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
StrongDecrease
HbA1c
HRS-7535 (30 mg) → HbA1c
HRS-7535 (30 mg) → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
StrongDecrease
Fasting Plasma Glucose (FPG)
HRS-7535 (60 mg) → Fasting Plasma Glucose (FPG)
HRS-7535 (60 mg) → Fasting Plasma Glucose (FPG)
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
StrongDecrease
HbA1c
HRS-7535 (60 mg) → HbA1c
HRS-7535 (60 mg) → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
StrongDecrease
Fasting Plasma Glucose (FPG)
HRS-7535 (90 mg) → Fasting Plasma Glucose (FPG)
HRS-7535 (90 mg) → Fasting Plasma Glucose (FPG)
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
StrongDecrease
HbA1c
HRS-7535 (90 mg) → HbA1c
HRS-7535 (90 mg) → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- HRS-7535 (60 mg) showed the greatest HbA1c reduction of 1.82%.
- Fasting plasma glucose decreased by 48.47 mg/dL with the 60 mg dose.
- Placebo showed minimal change in HbA1c and fasting plasma glucose.
Who this applies to
- Adults with type 2 diabetes inadequately controlled with metformin.
- Individuals seeking additional treatment options for blood sugar management.
Keep in Mind
- Results may not apply to those not on metformin.
- Further studies are needed to evaluate long-term effects.
- Variability in individual response to treatment may occur.
Between the Lines
- The study's population may not represent all adults with type 2 diabetes.
- Long-term safety and efficacy data are lacking.
- The sample size for each treatment group may limit generalizability.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on HRS-7535 (15 mg) and Fasting Glucose, HRS-7535 (15 mg) and HbA1c.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Fasting Glucose Evidence Hub
All studies measuring Fasting Glucose
1 studies
outcome_hubMeasures Fasting Glucose as a key outcome.
HbA1c Evidence Hub
All studies measuring HbA1c
1 studies
outcome_hubMeasures HbA1c as a key outcome.
HRS-7535 (15 mg) Evidence Hub
All studies on HRS-7535 (15 mg)
1 studies
intervention_hubContributes to HRS-7535 (15 mg) evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on HRS-7535 (15 mg) and Fasting Plasma Glucose (FPG)
Intervention: HRS-7535 (15 mg)Outcome: Fasting Plasma Glucose (FPG)
1 results
All studies on HRS-7535 (15 mg) and HbA1c
Intervention: HRS-7535 (15 mg)Outcome: HbA1c
1 results
All studies on HRS-7535 (15 mg)
Intervention: HRS-7535 (15 mg)
1 results
All studies measuring Fasting Plasma Glucose (FPG)
Outcome: Fasting Plasma Glucose (FPG)
1 results
All studies measuring HbA1c
Outcome: HbA1c
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does HRS-7535 (15 mg) improve fasting plasma glucose (fpg)?
Emerging Evidence
HRS-7535 (15 mg) appears to improve Fasting Plasma Glucose (FPG).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 52.9 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does HRS-7535 (15 mg) improve HbA1c?
Emerging Evidence
HRS-7535 (15 mg) appears to improve HbA1c.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 52.9 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does HRS-7535 (30 mg) improve fasting plasma glucose (fpg)?
Emerging Evidence
HRS-7535 (30 mg) appears to improve Fasting Plasma Glucose (FPG).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 52.9 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does HRS-7535 (30 mg) improve HbA1c?
Emerging Evidence
HRS-7535 (30 mg) appears to improve HbA1c.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 52.9 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Dietary supplements may lower diabetes risk in prediabetesNewer diabetes drugs show stronger weight and blood sugar benefits in prediabetesTaichi training improves lung function and blood sugar control in diabetesCombined Antioxidant and Prebiotic Supplementation Improves T2 Diabetes OutcomesDigital intervention improves glycemic control in type 2 diabetes patients
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.